Investment Summary

Hillhouse Invests In George Clinical

On December 9, 2022, private equity firm Hillhouse invested in life science company George Clinical

Investment Highlights
  • This is Hillhouse’s 2nd transaction in the Life Science sector.
  • This is Hillhouse’s 1st transaction in Australia.

Investment Summary
Date 2022-12-09
Target George Clinical
Sector Life Science
Investor(s) Hillhouse
Deal Type Growth Capital
Advisor(s) BofA Securities
Lazard Ltd. (Financial)
Herbert Smith Freehills (Legal)

Target

George Clinical

Newtown, Australia
George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers, for all trial phases, registration and post-marketing trials. George Clinical was founded in 2005 and is based in Newtown, Australia.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Hillhouse

Investor

Category Private Equity Firm
Founded 2005
Size Middle-Market
Type Sector Agnostic
DESCRIPTION

Hillhouse Capital Management is a private investment firm focused on opportunities throughout Asia. The Firm will invest at all company stages, including seed investments, buyouts, and listed equities. Areas of interest include consumer and health. Hillhouse Capital Management is based in Hong Kong.

DEAL STATS #
Overall 11 of 11
Sector (Life Science) 2 of 2
Type (Growth Capital) 2 of 2
Country (Australia) 1 of 1
Year (2022) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-08-25 AI Dream

Shanghai, China

AI Dream is a branded sleep solution provider and one of the largest players in China’s premium mattress market. Its differentiated product offering includes mattresses, bed frames, smart beds, and customized bedroom solutions. AI Dream was founded in 2018 and is based in Shanghai, China.

Buy -
Mergr

Product

Company

Legal